Scientific programme

OC7

Osteogenesis imperfecta - a pilot trial on treatment with the RANKL-antibody denosumab

Heike Hoyer-Kuhn (Cologne, Germany)

OC8

Combination sclerostin antibody and zoledronic acid treatment outperforms either treatment alone in a mouse model of osteogenesis imperfecta

Craig Munns (Sydney, Australia)

OC9

Skeletal manifestations in pediatric WNT1 osteoporosis

Riikka Mäkitie (Helsinki, Finland)

OC10

Lack of PEDF within the bone matrix is associated with osteoidosis and abnormally high bone mineral content

Nadja Fratzl-Zelman (Vienna, Austria)

OC11

Comparison of RANKL blockade and bisphosphonate anti-resorptive therapies in a growing mouse model of OI - implications of prolonged treatment on bone health

Cathleen Raggio (New York, USA)

OC12

A zebrafish osteogenesis imperfecta model: a new tool to develop novel pharmacological treatments

Roberta Gioia (Pavia, Italy)

OC13

Meclozine has a potential effects on short stature and foramen magnum stenosis in transgenic mice with achondroplasia

Masaki Matsushita (Nagoya, Japan)

OC14

Small interfering RNAs as an innovative therapeutic approach for the Autosomal Dominant Osteopetrosis type 2 (ADO2)

Mattia Capulli (L'Aquila, Italy)

OC15

Osseous side effects on the growing skeleton exerted by tyrosine kinase inhibitor treatment: data observed in pediatric patients with chronic myeloid leukemia in comparison to a juvenile rat model

Josephine T. Tauer (Dresden, Germany)

OC16

Medicarpin, a natural pterocarpan, enhances bone regeneration in cortical bone defect model by activation of notch and Wnt canonical signalling pathway

Manisha Dixit (Lucknow, India)

OC17

Inhibition of TGFβ signalling delays ossification in patients with fibrodysplasia ossificans progressiva

Coen Netelenbos (Hoofddorp, Netherlands)

OC18

Improvement in bone manifestations and respiratory status in infants and young children with HPP treated with asfotase alfa: an update on the ENB-010-10 trial

Christine Hofmann (Würzburg, Germany)

OP1

Skeletal and bone material phenotype in recessive osteogenesis imperfecta due to a novel homozygous point mutation in TMEM38B

Emma Webb (Birmingham, UK)

OP2

Abstract withdrawn

OP3

Increase of preosteoclasts and secretion of PDGF-BB by inhibition of cathepsin K activity increases mouse bone mass during development

Janet Crane (Baltimore, USA)

OP4

Transplantation of culture-expanded bone marrow cells and platelet rich plasma in lower limb lengthening for short stature patients

Hiroshi Kitoh (Nagoya, Japan)

OP5

Osteoclast phenotype of giant multinucleated cells in cherubism may determine the disease aggressiveness

Natacha Kadlub (Paris, France)

OP6

Genetic variation is involved in impairment of bone mineral density in long-term adult survivors of childhood cancer

M.A.H. den Hoed (Rotterdam, The Netherlands)

OP7

Lessons from homocystinuria: Cystathionine beta-synthase as a novel marker for osteogenic differentiation of human mesenchymal stem cells

Laura Gambari (Bologna, Italy)

OP8

Characterising the muscle-bone unit in children and adolescents with and without cystic fibrosis using novel imaging techniques and jumping mechanography

Kate Ward (Cambridge, UK)

OP9

Growth, body mass index, bone health and ambulatory status of boys with Duchenne Muscular Dystrophy (DMD) treated with daily versus intermittent oral glucocorticoid regimen

Nicola Crabtree (Birmingham, UK)

OP10

Does degree of adiposity influence upper limb fracture site in children?

Rebecca Moon (Southampton, UK)

OP11

Optimal dose of calcium for treatment of nutritional rickets

Tom Thacher (Rochester, USA)

OP12

A non-invasive method for screening vitamin D (Vit-D) insufficiency for adolescents using skin colourimetry

Tsz Ping Lam (Hong Kong, Hong Kong)

OC19

The VINE study: vitamin D in newborns. A randomized controlled trial comparing daily and bolus supplementation in breastfed infants of vitamin D deficient mothers

Christine Rodda (Melbourne, Australia)

OC20

The effect of calcium supplementation on adolescent bone growth in pre-pubertal Gambian females - A 12-year follow-up study

Kate Ward (Cambridge, UK)

OC21

Maternal vitamin D deficiency alters later skeletal responsiveness to mechanical loading in a model system

Stephanie Borg (Sheffield, UK)

OC22

Extra vitamin D from food fortification and bone fractures in adolescents: results from the D-tect study

Mina Nicole Händel (Frederiksberg, Denmark)

LB1

Maternal vitamin D depletion disrupts neonatal skeletal development in mice

Harriet Buckley (Sheffield, UK)

LB2

Recessive osteogenesis imperfecta caused by missense mutations in SPARC

Frank Rauch (Montreal, Canada)